Vejledninger, redskabsark og FAQta-ark


  1. Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease (updated 2015). Global Initiative for Chronic Obstructive Lung Disease; 2015.
  2. Lung-Function Trajectories Leading to Chronic Obstructive Pulmonary Disease N Engl J Med 2015; 373:111-122 July 9, 2015 DOI: 10.1056/NEJMoa1411532.
  3. Martinez, Fernando D n engl j med 375;9 September 1, 2016 Early-Life Origins of Chronic Obstructive Pulmonary Disease.
  4. Sundhedstyrelsens KOL-vejledning 2016.
  5. Danske KOL-guidelines 2012, Dansk Lungemedicinsk Selskab.
  6. Hayden LP, Hobbs BD, Cohen RT, et al. Childhood pneumonia increases risk for chronic obstructive pulmonary disease: the COPDGene study. Respir Res 2015;16:115.
  7. Guerra S, Stern DA, Zhou M, et al. Combined effects of parental and active smoking on early lung function deficits: a prospective study from birth to age 26 years. Thorax 2013;68:1021-8.
  8. Voraphani N, Stern DA, Wright AL, Guerra S, Morgan WJ, Martinez FD. Risk of current asthma among adult smokers with respiratory syncytial virus illnesses in early life. Am J Respir Crit Care Med 2014;190:392-8.
  9. Sundhedsstyrelsen: Dødsårsagsregistret. København. Sundhedsstyrelsen: 2011.
  10. Postma D, Bush A, van den Berge M. Risk factors and early origins of chronic obstructive pulmo-nary disease. Lancet 2014, published online August 12,2014.
  11. Stocks J, Hislop A, Sonnappa S. Early lung development: lifelong effect on respiratory health and disease. Lancet Respir Med 2013;1:728-42.
  12. Anbefalinger for tværsektorielle forløb for mennesker med KOL, Sundhedsstyrelsen 2015.
  13. Løkke et al Journal of COPD Juni 2014 vol. 11 no. 3.
  14. Løkke A, Lange P, Scharling H, Fabricius P, Vestbo J, Developing COPD – a 25 years follow-up study of the general population. Thorax 2006; 61:935-9.
  15. Lange, Ugeskr Læger 2012. Lange P, Marott JL, Dahl M, Ingebrigtsen TS, Vestbo J, Nordestgaard BG. Stort behov for ydelser til borgere med Kronisk obstruktiv lungesygdom. Ugeskr Læger 2012;174 (9).
  16. Fletcher C, Peto R. The natural history of chronic airflow obstruction. Br Med J 1977 Jun 25;1(6077):1645-8.
    Fletcher, Br Med J.1977. Fletcher C, Peto R. A prospective epidemiological study of the natural history of chronic airflow obstruction. Br Med J.1977;25;1:1645-8.
  17. Scanlon, Am J Respir Crit Care Med 2000. Scanlon PD, Connett JE, Waller LA, et al.. Smoking cessation and lung function in mild-to-moderate chronic obstructive pulmonary disease. The Lung Health Study. Am J Respir Crit Care Med 2000;161(2 Pt 1):381-90.
  18. Bednarek, Thorax 2006. Bednarek M, Gorecka D, Wielgomas J, et al. Smokers with airway obstruction are more likely to quit smoking. Thorax 2006;61(10):869.
  19. Ojedokun J, Keane S, O'Connor K. Journal of General Practice 2013;1(3) PMID: None.
  20. Parkes, BMJ 2008. Parkes G, Greenhalgh T, Griffin M, et al.Effect on smoking quit rate of telling patients their lung age: the Step2quit randomised controlled trial. BMJ 2008;336:598–600.
  21. Buffels J, Degryse J, Decramer M, Heyrman J. Spirometry and smoking cessation advice in general practice: a randomised clinical trial. Respir Med. 2006 Nov;100(11):2012-7. Epub 2006 Mar 31.
  22. Segnan N, Ponti A, Battista RN, et al. A randomized trial of smoking cessation interventions in general practice in Italy. Cancer Causes Control 1991 Jul;2(4):239-46. PMID: 1873454.
  23. Løkke, A, Marott, JL, Mortensen, J, Nordestgaard, BG, Dahl, M & Lange, P 2013, 'New Danish reference values for spirometry' Clinical Respiratory Journal, vol 7.
  24. Price D, Crockett A, Arne M, Garbe B, Jones RC, Kaplan A, Langhammer A, Williams S, Yawn BP. Spirometry in primary care case-identification, diagnosis and management of COPD. Prim Care Respir J 2009;18:216-23.
  25. From the Global Strategy for Asthma Management and Prevention, Global Initiative for Asthma (GINA) 2015.
  26. Drainsfield Lancet RM 2016, Wisdom.
  27. Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease (updated 2016). Global Initiative for Chronic Obstructive Lung Disease; 2016.
  28. National Institute for Health and Clinical Excellence. Chronic obstructive pulmonary disease: management of chronic obstructive pulmonary disease in adults in primary and secondary care. NICE clinical guideline 101. London: National Clinical Guideline Centre.; 2010.
  29. Celli BR, Cote CG, Marin JM, Casanova C, Montes de OM, Mendez RA, et al. The body-mass index, airflow obstruction, dyspnea, and exercise capacity index in chronic obstructive pulmonary disease. N Engl J Med 2004 Mar 4;350(10):1005-12.
    Celli BR, MacNee W. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur Respir J 2004 Jun;23(6):932-46.
  30. Nishimura K, Izumi T, Tsukino M, Oga T. Dyspnea is a better predictor of 5-year survival than airway obstruction in patients with COPD. Chest 2002 May;121(5):1434-40.
  31. Bestall JC, Paul EA, Garrod R, Garnham R, Jones PW, Wedzicha JA. Usefulness of the Medical Research Council (MRC) dyspnoea scale as a measure of disability in patients with chronic obstructive pulmonary disease. Thorax 1999 Jul;54(7):581-6.
  32. Garrod R, Marshall J, Barley E, Jones PW. Predictors of success and failure in pulmonary rehabilitation. Eur Respir J 2006 Apr;27(4):788-94.
  33. Wedzicha JA, Bestall JC, Garrod R, Garnham R, Paul EA, Jones PW. Randomized controlled trial of pulmonary rehabilitation in severe chronic obstructive pulmonary disease patients, stratified with the MRC dyspnoea scale. Eur Respir J 1998 Aug;12(2):363-9.
  34. Chronic obstructive pulmonary disease - management of chronic obstructive pulmonary disease in adults in primary and secondary care. National Institute for Clinical Excellence 2004 Feb.
  35. Standards for the diagnosis and Management of patients with COPD. American Thoracic Society and European Respiratory Society; 2004.
  36. Jones PW, Willits LR, Burge PS, Calverley PM. Disease severity and the effect of fluticasone propionate on chronic obstructive pulmonary disease exacerbations. Eur Respir J 2003 Jan;21(1):68-73.
  37. Friedman M, Serby CW, Menjoge SS, Wilson JD, Hilleman DE, Witek TJ, Jr. Pharmacoeconomic evaluation of a combination of ipratropium plus albuterol compared with ipratropium alone and albuterol alone in COPD. Chest 1999 Mar;115(3):635-41.
  38. Boushy SF, Thompson HK, Jr., North LB, Beale AR, Snow TR. Prognosis in chronic obstructive pulmonary disease. Am Rev Respir Dis 1973 Dec;108(6):1373-83.
  39. Burrows B, Earle RH. Course and prognosis of chronic obstructive lung disease. A prospective study of 200 patients. N Engl J Med 1969 Feb 20;280(8):397-404.
  40. Traver GA, Cline MG, Burrows B. Predictors of mortality in chronic obstructive pulmonary disease. A 15-year follow-up study. Am Rev Respir Dis 1979 Jun;119(6):895-902.
  41. O'Donnell DE, Revill SM, Webb KA. Dynamic hyperinflation and exercise intolerance in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001 Sep 1;164(5):770-7.
  42. Danske KOL-guidelines 2012, Dansk Lungemedicinsk Selskab.
  43. Lipovec NC, m.fl. (2016): The Prevalence of Metabolic Syndrome In Chronic Obstructive Pulmonary Disease: A Systematic Review, COPD: Journal of Chronic Obstructive Pulmonary Disease, DOI: 10.3109/15412555.2016.1140732.
  44. Loke YK et al: Risk of fractures with inhailed corticosteroids in COPD. Thorax 2011, 66(8) : 699-708.
  45. Mikkelsen RL, Middelboe T, Pisinger C, Stage KB. Anxiety and depression in patients with chronic obstructive pulmonary disease (COPD). Nord J Psychiatry 2004;58(1):65-70.
  46. Maurer J, Rebbapragada V, Borson S, Goldstein R, Kunik ME, Yohannes AM, Hanania NA. Anxiety and Depression in COPD. Current Understanding, Unanswered Questions, and Research Needs. Chest 2008 Supplement;134(4):43S-56S.
  47. DeJean D, Giacomini M, Vanstone M, Brundisini F. Patient Experiences of Depression and Anxiety with Chronic Disease: A Systematic Review and Qualitative Meta-Synthesis. Ontario Health Technology assessment series 2013;13(16):1-33.
  48. Pooler A, Beech R. Examining the relationship between anxiety and depression and exacerbations of COPD which result in hospital admission: a systematic review. International Journal of COPD 2014;9:315-330.
  49. Cafarella PA, Effing TW, Usmani Z, Frith PA. Treatments for anxiety and depression in patients with chronic obstructive pulmonary disease: Aliterary review. Respirology 2012;17:627-638.
  50. Coventry PA, Bower P, Keyworth C, Kenning C, Knopp J, Garrett C, Hind D, Malpass A, Dickens C. The effect of Complex Interventions on Depression and Anxiety in Chronic Obstructive Pulmonary Disease: Systematic Review and Meta.Analysis. PLOS ONE 2013;8(4):1-22.
  51. Jimmy Chong, Bonnie Leung and Phillippa Poole Phosphodiesterase 4 inhibitors for chronic obstructive pulmonary disease. Cochrane library November 2013.
  52. Falk. Tobakkens biologi ̧Tobakskaderådet (1994).
  53. Hansen NS. Tobakkens Biologi. København: Tobaksskaderådet, 2004.
  54. Røkeafvænning i primærtjenesten. Oslo: Social- og Helsedirektoratet 2004.
  55. Fiore MC, Bailey WC, Cohen SJ: Treating tobacco use and dependence. Clinical practical guideline no18 AHCPR pub no 96—0692. Rockvill MD;USDHHS Public Health Service 2000.
  56. Behandling af tobaksafhængighed – Anbefalinger til en styrket klinisk praksis Sundhedsstyrelsen 2011. URL:
  57. Godtfredsen NS & Tønnesen P: Rygestop og KOL UfL 175/18 s 1266-69, 2013.
  58. Silagy C et al. Nicotine replacement therapy for smoking cessation. Cohrane database syst rev 2004;(3): CD000146.
  59. Joerenby DE et al. A controlled trial of sustained-realised bupropion, a nicotine patch or both for smoking cessation. N Engl J Med 1999 4:340(9) 340-9.
  60. Sundhedsstyrelsen/notat E-cigaretter 06-01-2015.
  61. Baggrundsnotat for medicinsk behandling af patienter med KOL, RADS 2015.
  62. Wedzicha JA. Indacaterol–Glycopyrronium versus Salmeterol–Fluticasone for COPD. N Engl J Med 2016; 374:2222-2234.
  63. Appleton S, Smith B, Veale A et al. Long-acting beta 2-agonists for chronic obstructive pulmonary disease. (Cochrane Review). The Cochrane Library. Oxford: Update Software 2003;Isuue 3. Ref ID: 1137.
  64. National Institute for Clinical Excellence (NICE). Chronic obstructive pulmonary disease.
  65. Barr RG et al. Tiotropium for stable chronic obstructive pulmonary disease: a meta-analysis. Thorax 2006; 61: 854-62.
  66. Nannini JL, Lasserson TJ, Poole P. Combined corticosteroid and long-acting beta2-agonist in one inhaler versus long-acting beta2-agonists for chronic obstructive pulmonary disease. The Cochrane Libray September 2012.
  67. van der Valk P, Monninkhof E, Van der Palen J, Zielhuis G et al. Effect of discontinuation of inhaled corticosteroids in patients with chronic obstructive pulmonary disease: The COPE study. Am J Resp Crit Care Med 2002;166:1358-63.
  68. Wouters EFM, Postma DS, Fokkens B et al. Withdrawal of fluticasone propionate from combined salmeterol/fluticasone treatment in patients with COPD causes immediate and sustained disease deterioration: a randomised controlled trial. Thorax 2005;60:480-7.
  69. Pascoe S, Locantore N, Dransfield MT, Barnes NC, Pavord ID. Blood eosinophil counts, exacerbations, and response to the addition of inhaled fluticasone furoate to vilanterol in patients with chronic obstructive pulmonary disease: a secondary analysis of data from two parallel randomised controlled trials. Lancet Respir ICS Med.2015;3(6):435–442.
  70. Karner C, Cates CJ. The effect of adding inhaled corticosteroids to tiotropium and long-acting beta2-agonists for chronic obstructive pulmonary disease. The Cochrane Library May 2013.
  71. Kew KM, Seniukovich A. Inhaled steroids and risk of pneumonia for chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2014; 3: CD010115.
  72. Drummond MB, Dasenbrook EC, Patz MW et al. Inhaled Corticosteroids in Patients With Stable Chronic Obstructive Pulmonary Disease: A Systematic Review and Meta-analysis. JAMA. 2008;300(20):2407-2416.
  73. Herath SC, Poole P. Prophylactic antibiotic therapy for chronic obstructive pulmonary disease (COPD). The Cochrane Library November 2013.
  74. Ram FSF, Jones PW, Castro AA et al. Oral theophylline for chronic obstructive pulmonary disease. (Cochrane Review). The Cochrane Library 2003.
  75. Sutherland ER, Crapo JD, Bowler RP. N-acetylcysteine and exacerbations of chronic obstructive pulmonary disease. COPD. 2006 Dec;3(4):195-202.
  76. Köhnlein T, Windisch W, Köhler D, Drabik A, Geiseler J, Hartl S, Karg O, Laier-Groeneveld G, Nava S, Schönhofer B, Schucher B, Wegscheider K, Criée CP, Welte T. Non-invasive positive pressure ventilation for the treatment of severe stable chronic obstructive pulmonary disease: a prospective, multicentre, randomised, controlled clinical trial. Lancet Respir Med. 2014 Sep;2(9):698-705.
  77. Sundhedsstyrelsen. KOL - Kronisk Obstruktiv Lungesygdom. Anbefalinger for tidlig opsporing, opfølgning og rehabilitering af KOL. 2.0 ed. Sundhedsstyrelsen; 2007.
  78. Nici L, Donner C, Wouters E, Zuwallack R, Ambrosino N, Bourbeau J, et al. American Thoracic Society/European Respiratory Society statement on pulmonary rehabilitation. Am J Respir Crit Care Med 2006 Jun 15;173(12):1390-413.
  79. Lacasse Y, Goldstein R, Lasserson TJ, Martin S. Pulmonary rehabilitation for chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2006;(4):CD003793.
  80. Golmohammadi K, Jacobs P, Sin DD. Economic evaluation of a community-based pulmonary rehabilitation program for chronic obstructive pulmonary disease. Lung 2004;182(3):187-96.
  81. Puhan MA, Scharplatz M, Troosters T, Steurer J. Respiratory rehabilitation after acute exacerbation of COPD may reduce risk for readmission and mortality -- a systematic review. Respir Res 2005;6:54.
  82. Sundhedsstyrelsen 2014: National klinisk retningslinje for rehabilitering af patienter med KOL.
  83. Ringbaek T, Brondum E, Martinez G, Lange P. Rehabilitation in COPD: the long-term effect of a supervised 7-week program succeeded by a self-monitored walking program. Chron Respir Dis 2008;5(2):75-80.
  84. Anbefalinger for forebyggelsestilbud til borgere med kronisk sygdom, Sundhedsstyrelsen 2016.
  85. Schols AM, Soeters PB, Dingemans AM, Mostert R, Frantzen PJ, Wouters EF. Prevalence and characteristics of nutritional depletion in patients with stable COPD eligible for pulmonary rehabilitation. Am Rev Respir Dis 1993 May;147(5):1151-6.
  86. Landbo C, Prescott E, Lange P, Vestbo J, Almdal TP. Prognostic value of nutritional status in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1999 Dec;160(6):1856-61.
  87. Schols AM, Slangen J, Volovics L, Wouters EF. Weight loss is a reversible factor in the prognosis of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1998 Jun;157(6 Pt 1):1791-7.
  88. Celli BR, Calverley PM, Rennard SI, Wouters EF, Agusti A, Anthonisen N, et al. Proposal for a multidimensional staging system for chronic obstructive pulmonary disease. Respir Med 2005 Dec;99(12):1546-54.
  89. Vermeeren MA, Creutzberg EC, Schols AM, Postma DS, Pieters WR, Roldaan AC, et al. Prevalence of nutritional depletion in a large out-patient population of patients with COPD. Respir Med 2006 Aug;100(8):1349-55. Katsura H, Yamada K, Kida K. Both generic and disease specific health-related quality of life are deteriorated in patients with underweight COPD. Respir Med 2005 May;99(5):624-30.
  90. Katsura H, Yamada K, Kida K. Both generic and disease specific health-related quality of life are deteriorated in patients with underweight COPD. Respir Med 2005 May;99(5):624-30.
  91. Oostenbrink JB, Rutten-van Molken MP. Resource use and risk factors in high-cost exacerbations of COPD. Respir Med 2004 Sep;98(9):883-91.
  92. Ferreira IM, Brooks D, Lacasse Y, Goldstein RS, White J. Nutritional supplementation for stable chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2005;(2):CD000998.
  93. Creutzberg EC, Wouters EF, Mostert R, Weling-Scheepers CA, Schols AM. Efficacy of nutritional supplementation therapy in depleted patients with chronic obstructive pulmonary disease. Nutrition 2003 Feb;19(2):120-7.
  94. Roberts CM, Bugler JR, Melchor R, Hetzel MR, Spiro SG. Value of pulse oximetry in screening for long-term oxygen therapy requirement. Eur Respir J 1993 Apr;6(4):559-62.
  95. Iltbehandling i hjemmet. Dansk Lungemedicinsk Selskabs Kliniske retningslinjer. Dansk Lungemedicinsk Selskab 2015 ;
  96. Ann Intern Med 1980 Sep;93(3):391-8.Continuous or nocturnal oxygen therapy in hypoxemic chronic obstructive lung disease: a clinical trial. Nocturnal Oxygen Therapy Trial Group.
  97. Lancet 1981 Mar 28;1(8222):681-6.Long term domiciliary oxygen therapy in chronic hypoxic cor pulmonale complicating chronic bronchitis and emphysema. Report of the Medical Research Council Working Party.
  98. Zielinski J. Effects of long-term oxygen therapy in patients with chronic obstructive pulmonary disease. Curr Opin Pulm Med 1999 Mar;5(2):81-7.
  99. Balter MS, Daniak N, Chapman KR, Sorba SA, Rebuck AS. Erythropoietin response to acute hypoxemia in patients with chronic pulmonary disease. Chest 1992 Aug;102(2):482-5.
  100. Eaton T, Garrett JE, Young P, Fergusson W, Kolbe J, Rudkin S, et al. Ambulatory oxygen improves quality of life of COPD patients: a randomised controlled study. Eur Respir J 2002 Aug;20(2):306-12.
  101. Ringbaek TJ, Viskum K, Lange P. Does long-term oxygen therapy reduce hospitalisation in hypoxaemic chronic obstructive pulmonary disease. Eur Respir J 2002 Jul;20(1):38-42.
  102. Mehran RJ, Deslauriers J. Indications for surgery and patient work-up for bullectomy. Chest Surg Clin N Am 1995 Nov;5(4):717-34.
  103. Fessler HE, Permutt S. Lung volume reduction surgery and airflow limitation. Am J Respir Crit Care Med 1998 Mar;157(3 Pt 1):715-22.
  104. Poole PJ, Chacko E, Wood-Baker RW, Cates CJ. Influenza vaccine for patients with chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2000;(4):CD002733.
  105. SPC Prevenar 13® SmPC, 24. juni 2015.
  106. SPC Pneumovax SmPC,11.juni 2014.
  107. Epinyt 51b/2012.
  108. Torres A, Blasi F, Peetermans WE, Viegi G, Welte T. The aetiology and antibiotic management of community-acquired pneumonia in adults in Europe: a literature review. Eur J Clin Microbiol Infect Dis. 2014;33(7):1065-79.
  109. Epi-nyt 45/14.
  110. Kyaw MH, Rose CE, Fry AM, Singleton J a, Moore Z, Zell ER, Whitney CG: The influence of chronic illnesses on the incidence of invasive pneumococcal disease in adults. J Infect Dis 2005, 192:377–86.
  111. Van Hoek AJ, Andrews N, Waight PA, Stowe J, Gates P, George R, Miller E: The effect of underlying clinical conditions on the risk of developing invasive pneumococcal disease in England. J Infect 2012, 65:17–24.
  112. Folkehelseinstituttet: Anbefalinger for Bruk Av Pneumokokkvaksine Utenfor Barnevaksinasjonsprogram I Norge. 2013.
  113. Pneumokokvaccination uden for børnevaccinationsprogrammet i Danmark SSI 2014)
  114. Pollard AJ, Perrett KP, Beverley PC: Maintaining protection against invasive bacteria with protein-polysaccharide conjugate vaccines. Nat Rev Immunol 2009, 9:213–20.
  115. Fedson DS, Nicolas-Spony L, Klemets P, van der Linden M, Marques A, Salleras L, Samson SI: Pneumococcal polysaccharide vaccination for adults: new perspectives for Europe. Expert Rev Vaccines 2011, 10:1143–67.
  116. Moberley S, Holden J, Tatham DP, Andrews RM: Vaccines for preventing pneumococcal infection in adults. Cochrane database Syst Rev 2013, 1:CD000422.
  117. Eng P, Lim LH, Loo CM, Low JA, Tan C, Tan EK, Wong SY, Setia S: Role of pneumococcal vaccination in prevention of pneumococcal disease among adults in Singapore. Int J Gen Med 2014, 7:179–191.
  118. Scott JL: Drugs Aging 2012 oct29: 847-55 Pneumococcal polysaccharide conjugate vaccine – a guide to use in older adults.
  119. Sandford M, Bonten M: Community acquired pneumonia immunisation trial in adults N Engl J Med 2015; 373:91-93 July 2, 2015 DOI: 10.1056/NEJMc1505366.
  120. Sundhedsstyrelsen: Tilskudsklausul for 13-valent konjugeret pneumokokvaccine. 2015 (17. august).
  121. Martin Døssing, overlæge, dr. med., Frederikssund Sygehus, ”Lungesygdom og seksualitet” i bogen ”Krop, sygdom og seksualitet” fra 2006.
  122. Edvardsen A, Akerø A, Hardie JA, Ryg M, Eagan TML, Skjønsberg OH, Bakke PS. High prevalence of respiratory symptoms during airtravel in patients with COPD. Respir Med. 2011 Jan;105(1):50-6.
    Akerø A, Edvardsen A, Christensen CC, Owe JO, Ryg M, Skjønsberg OH. Chest 2011 Jul; 140(1):84-90. COPD and Air Travel:Oxygen Equipment and Preflight Titrationof Supplemental Oxygen.
  123. Zhang S, Robbins PA. Methodological and physiological variability within the ventilator respons to hypoxia in humans. J Appl Physiol 2000;88(5): 1924-1932 iol 2000;88(5): 1924-1932.
  124. Ahmedzai S, Balfour-Lynn IM, Bewick T m.fl: British Thoracic Society Standards of Care Committee. Managing passengers with stable respiratory disease planning air travel: British Thoracic Society recommendations. Thorax. 2011 Sep;66 Suppl 1.
  125. Robson A.G., Hartung T.K., Innes J.A. Laboratory assesment of fitness to fly in patients with lung disease: a practical approach. Eur Respir J 2000 Aug;16(2):214-9.
  126. Puhan, Cochrane 2011. Puhan MA et al. Pulmonary rehabilitation following exacerbations of chronic obstructive pulmonary disease. The Cochrane Library 2011.
  127. Huerst, NEJM. Huerst JR et al. Susceptibility to Exacerbation in Chronic Obstructive Pulmonary Disease. N Engl J Med 2010;363:1128-38.
  128. Larsen MV, Janner JH, Nielsen SD, Friis-Møller A, RingbaekT, Lange P. Bacteriology in acute eksacerbation of chronic obstructive pulmonary disease in patients admitted to hos- pital. Scand J Infect Dis. 2009;41:26-32.
  129. Julia AE Walters, Wendy Wang, Carla Morley, Amir Soltani and Richard Wood‐Baker Different durations of corticosteroid therapy for exacerbations of chronic obstructive pulmonary disease. The Cochrane Library 2012.
  130. Leupi JD, Schuetz P, Bingisser R et al. Short term vs. conventional glucocorticoid therapy in acute exacerbations of Chronic pulmonary disease. JAMA 309: 2223-31, 2013.
  131. Daniela J Vollenweider, Harish Jarrett, Claudia A Steurer‐Stey, Judith Garcia‐Aymerich and Milo A Puhan. Antibiotics for exacerbations of chronic obstructive pulmonary disease. The Cochrane Library 2012.
  132. Marså K et al. Dansk Lungemedicinsk Selskab: Klaringsrapport om palliation til voksne med kronisk fremadskridende non-malign lungesygdom, 2015. 

  133. Sundhedsstyrelsen. Anbefalinger for den palliative indsats, 2011.
  134. Singh SJ, ZuWallack RL, Garvey C, Spruit M a. Learn from the past and create the future: the 2013 ATS/ERS statement on pulmonary rehabilitation. Eur Respir J 2013; 42: 1169–74.
  135. Lungeforening D. Palliativ indsats til KOL-patienter. 2013.
  136. Patel K, Janssen DJ a, Curtis JR. Advance care planning in COPD. Respirology 2012; 17: 72–8.
  137. Strömgren AS, Groenvold M, Sorensen A, Andersen L. Symptom recognition in advanced cancer. A comparison of nursing records against patient self-rating., 2001 doi:450905 [pii].
  138. Strömgren AS, Groenvold M, Pedersen L, Olsen AK, Spile M, Sjøgren P. Does the medical record cover the symptoms experienced by cancer patients receiving palliative care. A comparison of the record and patient self-rating. J Pain Symptom Manage 2001; 21: 189–96.
  139. Jennings AL, Davies AN, Higgins JP et al. Opioids for the palliation of breathlessness in terminal illness. Cochrane Database Syst Rev 2001;4:CD002066.
  140. Simon ST, Higginson IJ, Booth S et al. Benzodiazepines for the relief of breathlessness in advanced malignant and non-malignant diseases in adults. Cochrane Database Syst Rev 2010;1:CD007354.
  141. Davidson PM, Johnson MJ. Update on the role of palliative oxygen. Curr Opin Support Palliat Care. 2011 ;5(2):87-91.
  142. Bausewein C, Booth S, Gysels M et al. Non-pharmacological interventions for breathlessness in advanced stages of malignant and non-malignant diseases. Cochrane Database Syst Rev 2008;2:CD005623.
  143. Ringbæk T, Wilcke JTR. Rehabilitering og palliation af patienter med svær KOL bør integreres. Ugeskrift for laeger, Vol. 175, No. 18, 2013, p. 1277-1280.
  144. Pinnock H, Kendall M, Murray SA, Worth A, Levack P, Porter M, MacNee W, Sheikh A. Living and dying with severe chronic obstructive pulmonary disease: multi-perspective longitudinal qualitative study. BMJ. 2011 24; 342.
  145. Momen N, Hadfield P, Kuhn I et al. Discussing an uncertain future: End-of-life care conversations in Chronic obstructive pulmonary disease. A systematic literature review and narrative synthesis. Thorax 2012;67:777-780.
  146. Nguyen HQ, Carrieri-Kohlman V. Dyspnea self-management in patients with chronic obstructive pulmonary disease: moderating effects of depressed mood. Psychosomatics 2005;46:402-10.
  147. Fan VS, Gaziano JM, Lew R, et al. A comprehensive care management program to prevent chronic obstructive pulmonary disease hospitalizations: a randomized, controlled trial. Ann. Intern. Med. 2012; 156: 673–83.
  148. (Lungefunktionsstandard) Lungefunktionsstandard - Spirometri og Peakflow. Dansk Lungemedicinsk Selskab 2007.